Following this, the American Food and Drug Administration and Health Canada approved the use of abemaciclib (CDK4/6 inhibitor) for patients with HR+/HER2− high-risk early breast cancer and a Ki-67 PI of ≥ 20%12. Here, HR is linked to breast carcinoma.